Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis

• Published in: Pharmacology Vol. 108; no. 3; pp. 255 - 264
• Main Authors: Krysiak, Robert, Kowalcze, Karolina, Okopień, Bogusław
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland 01.05.2023
• Subjects: Atorvastatin - pharmacology; Atorvastatin - therapeutic use; C-Reactive Protein - analysis; C-Reactive Protein - metabolism; C-Reactive Protein - therapeutic use; Cardiometabolic Risk Factors; Cardiovascular Diseases - prevention & control; Cholesterol; Female; Fibrinogen - analysis; Fibrinogen - therapeutic use; Hashimoto Disease - drug therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia - complications; Hypercholesterolemia - drug therapy; Research Article; Risk Factors; Thyroiditis, Autoimmune - complications; Thyroiditis, Autoimmune - drug therapy; Uric Acid; Hypercholesterolemia; 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; Pleiotropic effects; Autoimmune thyroiditis; Risk factors
• ISSN: 0031-7012; 1423-0313
• DOI: 10.1159/000529242

Abstract Introduction: Autoimmune thyroiditis seems to be associated with increased cardiometabolic risk. Statins, the mainstay of cardiovascular risk reduction and prevention, were found to reduce thyroid antibody titers. The aim of this study was to investigate plasma markers of cardiometabolic risk in statin-treated women with thyroid autoimmunity. Methods: We compared two matched groups of euthyroid women with hypercholesterolemia receiving atorvastatin treatment: subjects with autoimmune (Hashimoto’s) thyroiditis (group A, n = 29) and subjects without thyroid pathology (group B, n = 29). Plasma lipids, glucose homeostasis markers, as well as circulating levels of uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen, homocysteine, and 25-hydroxyvitamin D were measured before atorvastatin treatment and 6 months later. Results: At entry, both groups differed in antibody titers, insulin sensitivity, and plasma levels of uric acid, hsCRP, fibrinogen, homocysteine, and 25-hydroxyvitamin D. Atorvastatin-induced reduction in hsCRP and homocysteine, but not in total cholesterol and LDL-cholesterol, was more pronounced in group B than in group A. Only in group B, the drug decreased uric acid and fibrinogen and increased 25-hydroxyvitamin D. In group A, atorvastatin reduced insulin responsiveness. Conclusion: The obtained results indicate that euthyroid women with Hashimoto’s thyroiditis may benefit to a lesser degree from atorvastatin treatment than other populations of women with hypercholesterolemia.